Dysfunction of dendritic cells in tumor microenvironment and immunotherapy  

作　　者：Jie Chen Yuhang Duan Junye Che Jianwei Zhu 

机构地区：[1]Jecho Institute Co.,Ltd,Shanghai,P.R.China [2]Engineering Research Center of Cell&Therapeutic Antibody,Ministry of Education,Beijing,P.R.China [3]Shanghai Jiao Tong University,School of Pharmacy,Shanghai,P.R.China

出　　处：《Cancer Communications》2024年第9期1047-1070,共24页癌症通讯（英文）

基　　金：National Natural Science Foundation of China,Grant/Award Numbers:81773621,82073751;National Science and Technology Major Project,Grant/Award Number:2019ZX09732001-019。

摘　　要：Dendritic cells(DCs)comprise diverse cell populations that play critical roles in antigen presentation and triggering immune responses in the body.However,several factors impair the immune function of DCs and may promote immune evasion in cancer.Understanding the mechanism of DC dysfunction and the diverse functions of heterogeneous DCs in the tumormicroenvironment(TME)is critical for designing effective strategies for cancer immunotherapy.Clinical applications targeting DCs summarized in this report aim to improve immune infiltration and enhance the biological function of DCs to modulate the TME to prevent cancer cells from evading the immune system.Herein,factors in the TME that induce DC dysfunction,such as cytokines,hypoxic environment,tumor exosomes and metabolites,and co-inhibitory molecules,have been described.Furthermore,several key signaling pathways involved in DC dysfunction and signal-relevant drugs evaluated in clinical trials were identified.Finally,this review provides an overview of current clinical immunotherapies targeting DCs,especially therapies with proven clinical outcomes,and explores future developments in DC immunotherapies.

关 键 词：DCs immunotherapy dendritic cells dysfunction of DCs tumor microenvironment 

分 类 号：R730.51[医药卫生—肿瘤]